About
Daniel M. Clemens is a biotechnology scientist and drug-development executive focused on cardiovascular and age-related disease. He serves as Vice President of Biology at Cyclarity Therapeutics, where he works on cyclodextrin-based therapeutics targeting oxidized cholesterol and atherosclerosis. Cyclarity states that he earned a B.S. in biochemistry from UCLA in 2004 and a Ph.D. in biomedical sciences from UC Irvine in 2013.
Areas of interest
biotechlongevityatherosclerosiscardiovascular diseasedrug developmentclinical developmentcyclodextrin therapeuticsoxidized cholesterol